Nsclc

Immunotherapy for NSCLC - Video abstract 57550

Order: Reorder
Duration: 4:14
Updated: 03 Feb 2014

Video abstract of review paper "New modalities of cancer treatment for NSCLC: focus on immunotherapy" published in the open access journal Cancer Management and Research by Davies. Abstract: Recent advances in the understanding of immunology and antitumor immune responses have led to the development of new immunotherapies, including vaccination approaches and monoclonal antibodies that inhibit immune checkpoint pathways. These strategies have shown activity in melanoma and are now being tested in lung cancer. The antibody drugs targeting cytotoxic T-lymphocyte-associated antigen-4 and programmed cell death protein-1 immune checkpoint pathways work by restoring immune responses against cancer cells, and are associated with unconventional response patterns and immune-related adverse events as a result of their mechanism of action. As these new agents enter the clinic, nurses and other health care providers will require an understanding of the unique efficacy and safety profiles with immunotherapy to optimize potential patient benefits. This paper provides a review of the new immunotherapeutic agents in development for lung cancer, and strategies for managing patients on immunotherapy. Read the review paper here: http://www.dovepress.com/new-modalities-of-cancer-treatment-for-nsclc-focus-on-immunotherapy-peer-reviewed-article

http://wn.com/Immunotherapy_for_NSCLC_Video_abstract_57550

Molecular Therapeutics for NSCLC

Order: Reorder
Duration: 28:01
Updated: 30 Jul 2012

Edward Kim, MD; MD Anderson Cancer Center.

http://wn.com/Molecular_Therapeutics_for_NSCLC

Recent developments in targeted therapy for NSCLC

Order: Reorder
Duration: 55:52
Updated: 31 Dec 2012

Mark G. Kris, MD (speaker) Gregory Riely, MD, PhD (moderator) Recorded at Sloan Kettering (NY) on December 11th, 2012.

http://wn.com/Recent_developments_in_targeted_therapy_for_NSCLC

Lung Cancer Clinical Trial for NSCLC

Order: Reorder
Duration: 7:16
Updated: 15 Nov 2013

A new and innovative lung cancer clinical trial is being conducted at UCLA. This trial tests the use of an aromatase inhibitor in conjunction with the standard lung cancer chemotherapy to find better treatments and hopefully cures for lung cancer. This trial is based upon the concept that estrogen serves as the basic fuel for lung cancer. The trial is for advanced non-small cell lung cancer (NSCLC).

http://wn.com/Lung_Cancer_Clinical_Trial_for_NSCLC

Segment 2: Molecular Targets in NSCLC

Order: Reorder
Duration: 26:57
Updated: 03 Apr 2014

Three renowned experts in the field of lung cancer, Dr. Mark Kris from MSKCC and Drs. Lecia Sequist and Alice Shaw from Harvard Medical School, join Dr. Jim Epstein to discuss the different molecular aberrations contributing to the pathogenesis and progression of NSCLC as they provide insights into the importance of testing for these abnormalities and the impact that results will have on treatment decisions and outcomes. In this segment of the DocTalk: Opinion Leader Workshop in Non-Small Cell Lung Cancer, Dr. Alice T. Shaw discusses molecular targets in NSCLC. Earn accreditation for this activity at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7050 © 2014 Imedex, LLC.

http://wn.com/Segment_2_Molecular_Targets_in_NSCLC

Segment 1: EGFR TKIs in NSCLC

Order: Reorder
Duration: 28:17
Updated: 03 Apr 2014

Three renowned experts in the field of lung cancer, Dr. Mark Kris from MSKCC and Drs. Lecia Sequist and Alice Shaw from Harvard Medical School, join Dr. Jim Epstein to discuss the different molecular aberrations contributing to the pathogenesis and progression of NSCLC as they provide insights into the importance of testing for these abnormalities and the impact that results will have on treatment decisions and outcomes. In this segment of the DocTalk: Opinion Leader Workshop in Non-Small Cell Lung Cancer, Dr. Lecia V. Sequist discusses the use of EGFR TKIs in NSCLC. Earn accreditation for this activity at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7050 © 2014 Imedex, LLC.

http://wn.com/Segment_1_EGFR_TKIs_in_NSCLC

Case Study: Progression on ALK Inhibitors in NSCLC

Order: Reorder
Duration: 6:04
Updated: 01 Oct 2013

In the continuation of a case-based discussion, panelists discuss treatment options following progression on crizotinib for a 46 year-old woman with ALK-positive NSCLC. To view more from this discussion, visit http://www.onclive.com/peer-exchange/nsclc-therapies

http://wn.com/Case_Study_Progression_on_ALK_Inhibitors_in_NSCLC

GRACEcast-028_Lung-Cancer_Heather Wakelee on NSCLC Adjuvant Therapy

Order: Reorder
Duration: 17:16
Updated: 24 Jul 2011

http://cancergrace.org/ This slide presentation by Dr. Heather Wakelee, medical oncologist at Stanford University, describes the current evidence supporting ...

http://wn.com/GRACEcast-028_Lung-Cancer_Heather_Wakelee_on_NSCLC_Adjuvant_Therapy

Long Term Management of EGFR-Mutant NSCLC -Tsao

Order: Reorder
Duration: 21:35
Updated: 21 May 2013

Recorded at the 19th Annual Meeting of the Network of Oncology Clinicians and Researchers (NOCR) 2013. Earn CME at: http://elc.imedex.com.

http://wn.com/Long_Term_Management_of_EGFR-Mutant_NSCLC_-Tsao

GRACEcast-076_Lung-Cancer_ASCO 2011 Highlights - SCLC, Early Stage NSCLC and Mesothelioma

Order: Reorder
Duration: 40:09
Updated: 01 Mar 2012

http://cancergrace.org/ Dr. Mary Pinder-Schenck from the H. Lee Moffitt Cancer Center in Tampa, FL reviews highlights of presentations on small cell lung can...

http://wn.com/GRACEcast-076_Lung-Cancer_ASCO_2011_Highlights_SCLC,_Early_Stage_NSCLC_and_Mesothelioma

Dr. Scagliotti Discusses EGFR Mutations in NSCLC

Order: Reorder
Duration: 1:37
Updated: 16 Sep 2011

Giorgio V. Scagliotti, MD, PhD, head of the Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, ...

http://wn.com/Dr_Scagliotti_Discusses_EGFR_Mutations_in_NSCLC

ASCO Lung Cancer Highlights, Part 1: Introduction to Stage III NSCLC

Order: Reorder
Duration: 7:44
Updated: 07 Aug 2013

http://cancerGRACE.org/ Dr. David Gerber, University of Texas-Southwestern, reviews the current questions in managing locally advanced NSCLC with chemo/radia...

http://wn.com/ASCO_Lung_Cancer_Highlights,_Part_1_Introduction_to_Stage_III_NSCLC

NSCLC Therapeutics in Asia-Pacific Markets to 2019

Order: Reorder
Duration: 1:00
Updated: 10 Mar 2014

The collection of 'Respiratory therapeutics' market research reports has a new addition of "NSCLC Therapeutics in Asia-Pacific Markets to 2019 -- Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool" on RnRMarketResearch.com. GBI Research, the leading business intelligence provider, has released its latest research: 'NSCLC Therapeutics in APAC Markets to 2019 -- Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool', which provides in-depth insights into the Non-Small Cell Lung Cancer (NSCLC) indication. The report provides an estimation of the market size for 2012 along with market forecasts until 2019 for the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, clinical trial analysis (including failure rates), pipeline analysis, and analysis of deals relevant to NSCLC. The NSCLC market in the APAC region is estimated to have been worth $1.8 billion in 2012 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.3% to reach $2.9 billion by 2019. The key drivers for this growth include an aging population, an increasing number of NSCLC incident cases and the expected launch of promising therapies. Complete report is available @ http://www.rnrmarketresearch.com/nsclc-therapeutics-in-asia-pacific-markets-to-2019-personalized-therapies-focus-on-untapped-segment-of-squamous-cell-carcinoma-to-expand-treatment-pool-market-report.html

http://wn.com/NSCLC_Therapeutics_in_Asia-Pacific_Markets_to_2019

GRACEcastUC-004 - Why is Chemotherapy Recommended for Most Patients with NSCLC?

Order: Reorder
Duration: 2:31
Updated: 22 Nov 2012

http://cancerGRACE.org/ Dr. H. Jack West, medical oncologist from Swedish Cancer Institute in Seattle, WA, reviews the rationale for giving chemotherapy to p...

http://wn.com/GRACEcastUC-004_Why_is_Chemotherapy_Recommended_for_Most_Patients_with_NSCLC?

Dr. Belani on Treating NSCLC with Nintedanib

Order: Reorder
Duration: 1:18
Updated: 15 Jan 2014

Chandra P. Belani, MD, Deputy Director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses the VEGF-targeted agent nintedanib (BIBF 1120). For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/

http://wn.com/Dr_Belani_on_Treating_NSCLC_with_Nintedanib

Dr. Paz-Ares Discusses the Use of Pemetrexed for NSCLC

Order: Reorder
Duration: 0:35
Updated: 17 Jun 2011

Luis Paz-Ares, MD, PhD the chair of oncology at Seville University Hospital in Spain discusses the use of pemetrexed in advanced nonsquamous non--small cell ...

http://wn.com/Dr_Paz-Ares_Discusses_the_Use_of_Pemetrexed_for_NSCLC

Debate: What is the optimal chemotherapy for stage III NSCLC? - Taxane/carboplatin is the standard

Order: Reorder
Duration: 11:05
Updated: 15 Aug 2013

With the advancements in the treatment of NSCLC, several thought-provoking issues challenge the thoracic oncologists' perspectives in the optimal management of their patients with lung cancers. The best combination of agents, timing and duration of therapies, patient selection, and appropriate clinical utilization of biomarkers are being considered. The Great Debates and Updates in Thoracic Malignancies 2013 meeting chaired by Dr. Ramaswamy Govindan provides expert-led updates, debates, and discussions of emerging research findings in the field of thoracic malignancies, with the goal of bringing clinicians closer to consensus on these important controversies. Earn accreditation for this activity at the following location: http://elc.imedex.com/ELC/Activity-Detail.aspx?activityid=6860 © 2013 Imedex, LLC.

http://wn.com/Debate_What_is_the_optimal_chemotherapy_for_stage_III_NSCLC?_Taxane_carboplatin_is_the_standard

Ganetespib (STA-9090) as Monotherapy in Patients with Advanced NSCLC

Order: Reorder
Duration: 3:39
Updated: 29 Jul 2013

From ASCO 2011 -- A discussion with Vojo Vukovic, MD, Chief Medical Officer at Synta Pharmaceuticals on the Hsp90 inhibitor ganetespib (STA-9090). Please see...

http://wn.com/Ganetespib_STA-9090_as_Monotherapy_in_Patients_with_Advanced_NSCLC

Concurrent Versus Sequential Testing in NSCLC

Order: Reorder
Duration: 5:40
Updated: 04 Feb 2013

Corey J. Langer, MD, Alan B. Sandler, MD, Mark A. Socinski, MD, Anne S. Tsao, MD, and David Gandara, MD, discuss concurrent versus sequential testing in non-...

http://wn.com/Concurrent_Versus_Sequential_Testing_in_NSCLC

Matthew Stephen Lara on Younger Vs Older Patients With NSCLC

Order: Reorder
Duration: 0:56
Updated: 16 Jul 2013

Primo Lara, MD, and his son, Matthew Stephen Lara, discuss an analysis of predictors of survival for younger patients with non-small cell lung cancer (NSCLC)...

http://wn.com/Matthew_Stephen_Lara_on_Younger_Vs_Older_Patients_With_NSCLC

Determining When to Administer Maintenance Therapy in NSCLC

Order: Reorder
Duration: 7:46
Updated: 13 May 2014

Panelists discuss the factors that contribute to the decision making process for the administration of maintenance therapy in patients with non-small cell lung cancer. To view more from this segment, visit http://www.onclive.com/peer-exchange/nsclc-outcomes

http://wn.com/Determining_When_to_Administer_Maintenance_Therapy_in_NSCLC

Dr. Shaw Discusses LDK378 and Alectinib (AF802) for ALK-Positive NSCLC

Order: Reorder
Duration: 2:32
Updated: 10 Feb 2014

Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses the two most advanced next-generation ALK-inhibitors for the treatment of non-small cell lung cancer (NSCLC): LDK378 and alectinib (AF802). More on lung cancer: http://www.onclive.com/specialty/lung-cancer

http://wn.com/Dr_Shaw_Discusses_LDK378_and_Alectinib_AF802_for_ALK-Positive_NSCLC

Dr. Heather Wakelee Discusses Nintedanib Plus Chemotherapy in NSCLC

Order: Reorder
Duration: 1:56
Updated: 09 Aug 2013

Heather Wakelee, MD, an assistant professor at the Stanford University School of Medicine and member of the Stanford Cancer Institute, describes two phase III trials presented at the 2013 ASCO Annual Meeting that focused on the second-line administration of the oral triple angiokinase inhibitor nintedanib (BIBF 1120) plus chemotherapy to treat patients with advanced non-small cell lung cancer (NSCLC). For more lung cancer resources, visit http://www.onclive.com/specialty/lung-cancer

http://wn.com/Dr_Heather_Wakelee_Discusses_Nintedanib_Plus_Chemotherapy_in_NSCLC